OBI Pharma
Company Details
Status: Public
Employees: 101-250
Location:
Taipei City, Taiwan
Type:
sample
Technology:
sample
sample
sample
sample
About: OBI Pharma, Inc. is a Taiwan based bio-pharma company founded in 2002. Our mission is to improve health and the quality of life through innovative cancer therapeutics. We seek to develop and license novel therapeutic agents for unmet medical needs against cancer by targeting the Globo Series antigens (Globo H, SSEA-4), the AKR1C3 enzyme, and other promising targets. Our leading compound is Adagloxad simolenin, a late-stage novel active immuno-oncology (IO) Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer.
OBI has a full spectrum of Globo Series IO pipeline, which includes both active (vaccine) and passive (monoclonal antibody & antibody drug conjugate) therapeutics. Development of OBI-888 (Globo H monoclonal antibody), OBI-833 (Globo Series vaccine) for epithelial cancers, OBI-999 (Globo H antibody drug conjugate), OBI-898 (SSEA-4 monoclonal antibody), and OBI-866 (SSEA-4 vaccine) for multiple cancers are also underway.
In addition, development of OBI-3424, a novel First-in-Class compound targeting both solid and liquid that express the Aldo Keto Reductase 1C3 enzyme, further enriches the company’s pipeline profile.
OBI Pharma, Inc. is publicly listed on the Taipei Exchange (TPEx: 4174); wholly-owned subsidiaries are present in the United States and China. The company is led by management team with a track record of success in new drug development and commercialization.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
OBI Pharma | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.